LogicBio Therapeutics Stock Forecast, Price & News

-0.18 (-2.84 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $6.16
50-Day Range
MA: $7.80
52-Week Range
Now: $6.16
Volume6,725 shs
Average Volume129,178 shs
Market Capitalization$197.28 million
P/E RatioN/A
Dividend YieldN/A
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.
LogicBio Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:LOGC
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$1.84 per share


Net Income$-40,130,000.00


Market Cap$197.28 million
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable


LogicBio Therapeutics Inc. Regi (0IF.SG)
January 1, 2021 |
Looking In On LogicBio
November 17, 2020 |
FDA places hold on Huntington's gene therapy trial
October 13, 2020 |
See More Headlines


Overall MarketRank

1.31 out of 5 stars

Medical Sector

786th out of 2,011 stocks

Biological Products, Except Diagnostic Industry

112th out of 176 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.18 (-2.84 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

Is LogicBio Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than LogicBio Therapeutics?

Wall Street analysts have given LogicBio Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LogicBio Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting LogicBio Therapeutics?

LogicBio Therapeutics saw a increase in short interest in February. As of February 26th, there was short interest totaling 827,300 shares, an increase of 22.1% from the February 11th total of 677,700 shares. Based on an average daily volume of 144,700 shares, the short-interest ratio is presently 5.7 days. Approximately 4.6% of the company's shares are short sold.
View LogicBio Therapeutics' Short Interest

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for LogicBio Therapeutics

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) released its quarterly earnings results on Sunday, March, 14th. The company reported ($0.22) EPS for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.11. The firm earned $0.54 million during the quarter.
View LogicBio Therapeutics' earnings history

How has LogicBio Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LOGC shares have decreased by 12.5% and is now trading at $6.16.
View which stocks have been most impacted by COVID-19

What price target have analysts set for LOGC?

3 equities research analysts have issued twelve-month target prices for LogicBio Therapeutics' shares. Their forecasts range from $17.00 to $20.00. On average, they expect LogicBio Therapeutics' stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 200.3% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau M.B.A., Pres, CEO & Director (Age 54, Pay $632.9k)
  • Dr. Mark A. Kay, Co-Founder & Independent Director (Age 63, Pay $102.5k)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel Ph.D., Co-Founder
  • Ms. Cecilia Jones, Chief Financial Officer
  • Dr. Kyle Chiang Ph.D., Chief Operating Officer
  • Dr. Matthias Hebben, Global VP & Head of Technology Devel.
  • Ms. Mariana Nacht, Chief Scientific Officer
  • Mr. Matthias B. Jaffe, Consultant (Age 52)
  • Dr. Daniel J. Gruskin M.D., Sr. VP & Head of Clinical Devel.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $6.16.

How much money does LogicBio Therapeutics make?

LogicBio Therapeutics has a market capitalization of $197.28 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does LogicBio Therapeutics have?

LogicBio Therapeutics employs 39 workers across the globe.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is

Where are LogicBio Therapeutics' headquarters?

LogicBio Therapeutics is headquartered at 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.